EMA says no on designating alternative to qualified person for pharmacovigilance database
This article was originally published in SRA
Executive Summary
The European Medicines Agency has clarified that a drug company's qualified person for pharmacovigilance (QPPV) is not allowed to designate an alternative contact point for issues regarding the Article 57 database of medicinal products that was created under the EU pharmacovigilance legislation.